Showing results (251-260 of 285) with videos related to

Sort By:
Pageof 29
BMC Cancer|November 5, 2020
RX-5902, a novel β-catenin modulator, potentiates the efficacy of immune checkpoint inhibitors in preclinical models of triple-negative breast CancerJohn J Tentler, Julie Lang, Anna Capasso, et al.
Journal of Applied Clinical Medical Physics|February 27, 2018
COMP report: CPQR technical quality control guidelines for radiation treatment centersKyle E Malkoske, Michelle K Nielsen, Laurent Tantôt, et al.
Scientific Data|November 1, 2019
7 Tesla MRI of the ex vivo human brain at 100 micron resolutionBrian L Edlow, Azma Mareyam, Andreas Horn, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 18, 2020
Sacituzumab govitecan in previously treated hormone receptor-positive/HER2-negative metastatic breast cancer: final results from a phase I/II, single-arm, basket trialK Kalinsky, J R Diamond, L T Vahdat, et al.
BMC Cancer|October 30, 2022
ATM kinase inhibitor AZD0156 in combination with irinotecan and 5-fluorouracil in preclinical models of colorectal cancerS Lindsey Davis, Sarah J Hartman, Stacey M Bagby, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 14, 2021
A Phase I Study of an MPS1 Inhibitor (BAY 1217389) in Combination with Paclitaxel Using a Novel Randomized Continual Reassessment Method for Dose EscalationFlorence Atrafi, Oliver Boix, Vivek Subbiah, et al.
Cancer Chemotherapy and Pharmacology|February 26, 2021
A phase I pharmacokinetic and safety study of Paclitaxel Injection Concentrate for Nano-dispersion (PICN) alone and in combination with carboplatin in patients with advanced solid malignancies and biliary tract cancersWen Wee Ma, Mojun Zhu, Elaine T Lam, et al.
Cancers|April 27, 2024
A Phase Ib Expansion Cohort Evaluating Aurora A Kinase Inhibitor Alisertib and Dual TORC1/2 Inhibitor Sapanisertib in Patients with Advanced Solid TumorsS Lindsey Davis, Wells A Messersmith, W Thomas Purcell, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 7, 2010
Phase I safety, pharmacokinetic, and pharmacodynamic study of ENMD-2076, a novel angiogenic and Aurora kinase inhibitor, in patients with advanced solid tumorsJennifer R Diamond, Bruno R Bastos, Ryan J Hansen, et al.
NPJ Breast Cancer|June 10, 2022
Sacituzumab govitecan as second-line treatment for metastatic triple-negative breast cancer-phase 3 ASCENT study subanalysisLisa A Carey, Delphine Loirat, Kevin Punie, et al.
Pageof 29